Sugammadex Sodium Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable

Sugammadex sodium is a synthetic modified γ-cyclodextrin supplied as a pharmaceutical-grade active substance with the molecular formula C72H104Na8O48S8, a molecular weight of 2178.0 g/mol, and CAS registry number 343306-79-6. The material is a single defined chemical entity rather than a degree-substituted cyclodextrin mixture; this distinguishes it from hydroxypropyl-β-cyclodextrin and sulfobutylether-β-cyclodextrin, which are heterogeneous substitution products. The API is supplied in two process grades: an injectable grade with low bioburden and controlled bacterial endotoxins, and an oral solid grade with defined particle-size distribution for tablet, capsule, and granule manufacture. Both grades are manufactured under ICH Q7 GMP conditions and are supported by a regulatory technical data package that includes stability data generated according to ICH Q1A.

The injectable grade is differentiated by a route-specific release panel because it will be dissolved and sterile-filtered before aseptic filling. The oral solid grade is differentiated by powder flow, particle-size distribution, and water content controls relevant to direct compression, capsule filling, and granule sachet filling. A non-GMP research or technical grade of sugammadex sodium is not interchangeable with either process grade for human-use manufacture.

Differential Release Specifications for Oral Solid Dose and Injectable Manufacturing

The release panel is not identical for the two dosage-form routes. Parenteral-grade material is controlled for microbial quality and endotoxin because the API will be dissolved and sterile-filtered; oral solid-grade material is controlled primarily for particle-size distribution, water content, and residual solvent limits. The following table summarizes the control logic and reference methods used for batch release.

The values in the table are route-specific and should be transferred into the applicant’s specification only after confirmation against the intended maximum daily dose and final product formulation. The assay and related substances methods are validated by high-performance liquid chromatography according to ICH Q2(R1). Residual solvent profiles are established by headspace gas chromatography. Elemental impurities are screened by inductively coupled plasma mass spectrometry according to ICH Q3D; the oral and parenteral permitted daily exposure routes differ, so the injectable grade is not automatically interchangeable with the oral grade on the certificate of analysis.

How Does Sugammadex Sodium Compare with Cholinesterase Inhibitors and Solubilizing Cyclodextrins?

Mechanistically, sugammadex sodium is not an enzyme inhibitor. It encapsulates steroidal neuromuscular blocking agents such as rocuronium and vecuronium by forming a 1:1 host–guest complex, thereby reducing free drug concentration at the nicotinic receptor. This differs from neostigmine methylsulfate, which inhibits acetylcholinesterase and requires coadministration of an antimuscarinic agent. The macrocycle has no direct effect on acetylcholine; it does not require muscarinic blockade, and it is not a cholinesterase substrate.

As an API for compounding, sugammadex sodium is also distinct from common parenteral cyclodextrin solubilizers. Hydroxypropyl-β-cyclodextrin and sulfobutylether-β-cyclodextrin are used as formulation vehicles to solubilize poorly water-soluble drugs; they are excipients. Sugammadex sodium is the active substance. It is a fully substituted γ-cyclodextrin derivative with a discrete molecular mass of 2178.0 g/mol, whereas the parenteral solubilizers are substitution-level mixtures with average molecular-weight distributions rather than a single molecular species. The side-chain design gives selective affinity for steroidal neuromuscular blocking agents and does not function as a general-purpose inclusion host for neutral lipophilic molecules.

Differentiation from technical or research-grade sugammadex sodium is based on the route-specific release panel and GMP documentation. Technical material may contain undefined process impurities, may not be tested for elemental impurities according to ICH Q3D, and is not supported by stability data under ICH Q1A. Even within pharma grades, oral-grade and injectable-grade material must not be interchanged without a batch-specific review, because the elemental impurity and microbial quality requirements for parenteral use are tighter.

In oral solid-dose development, the main process variables are powder flow, moisture sensitivity, and content uniformity. Because the API is freely soluble in water, wet granulation can produce localized overwetting and bowl adhesion in high-shear mixers; when wet granulation is used, the binder solution is added at a reduced spray rate and the impeller speed is maintained below the threshold at which the API begins to dissolve and form agglomerates. A more robust route for low-dose tablets is dry granulation by roller compaction. The API is preblended with filler and disintegrant in a V-blender with an intensifier bar at 25–35 rpm for 10–15 min; the blend is compacted to ribbon density 1.1–1.3 g/cm³, milled through a screen of 0.8–1.0 mm, and then compressed on a rotary tablet press. Content uniformity is checked according to USP <905>, and dissolution is evaluated with USP <711> Apparatus II at 50 rpm in 900 mL of water at 37 °C.

For capsule products, the milled granule or direct powder blend is filled into hard gelatin or hypromellose shells using a dosator or tamping-pin machine. Powder bridging at the hopper outlet is a known bottleneck; the controlled water content below 2.0% and the addition of 0.5–1.0% colloidal silicon dioxide reduce bridging and improve flow without affecting the dissolution profile. Granule sachet presentations require the same particle-size control but with a final packaging step in aluminum-laminate sachets because moisture ingress through low-barrier packaging can raise the water content above the release limit during storage.

When Dry Granulation Is Selected to Avoid Wet-Mass Stickiness

Dry granulation is the preferred route when the formulation cannot tolerate aqueous binder addition. The primary process conflict is that excessive roll pressure reduces granule porosity and delays tablet disintegration, while insufficient roll pressure produces a high-fines blend that segregates in the granule feed system. Batch records from rotary tablet presses show that a milled granule with D50 250–400 µm and a fines fraction below 20% by sieve analysis improves die filling and reduces weight variation to not more than 2.0%. The roll force is set to achieve the target ribbon density; the mill speed is adjusted to maintain product temperature below 40 °C during size reduction because thermal stress can increase related substances and alter the color of the powder.

The injectable-grade API is not distributed as a sterile powder. It is a non-sterile active substance with a low bioburden and defined endotoxin level that will be dissolved in Water for Injection at a concentration equivalent to 100 mg/mL sugammadex and sterilized by membrane filtration through a 0.22 µm polyethersulfone or polyvinylidene fluoride filter before aseptic filling. Typical final drug product dosing follows the reference product label: 2 mg/kg for reversal of moderate rocuronium-induced blockade, 4 mg/kg for deep blockade, and 16 mg/kg for immediate reversal after 1.2 mg/kg rocuronium. Because the dose is expressed on body weight and can reach several hundred milligrams in adults, the endotoxin limit for the API must be calculated from the maximum dose using USP <85>; the applicant cannot simply adopt a standard oral API limit.

Published data for oral sugammadex sodium in systemic reversal are limited. The high molecular weight, anionic charge, and low octanol–water partition coefficient suggest minimal passive intestinal permeability. Accordingly, tablet, capsule, or granule presentations are not interchangeable with the parenteral product for rocuronium or vecuronium reversal; any oral solid-dose investigation should define the intended non-systemic target separately.

Injectable Processing Boundaries and Container Closure Requirements

Solution preparation for parenteral manufacture is performed in closed stainless-steel vessels under nitrogen inerting. The API is added to Water for Injection with slow agitation; high-shear mixing is not required, and excessive vortexing is avoided because air entrainment can produce foaming. The final adjusted solution is typically filled into Type I glass vials with chlorobutyl rubber stoppers and flip-off seals. Particulate matter is controlled by USP <788>; sterility is validated by membrane filtration according to USP <71> or Ph. Eur. 2.6.1. The reference product label indicates a clear, colorless to slightly yellow solution with a concentration of 100 mg/mL; diluted admixtures in 0.9% sodium chloride may be used within 24 hours at 25 °C.

The sugammadex–rocuronium complex is primarily renally cleared; patients with creatinine clearance below 30 mL/min show prolonged exposure, and the diluted injection must be visually inspected for particulate matter before administration. The API itself should be stored in moisture-tight containers protected from light at 15–25 °C; repeated opening introduces moisture and microbial risk, so a partial-use requalification plan based on water content and bioburden testing is required for multi-opening drums.